Sentences with phrase «with placebo treatments»

The researchers called for more studies to compare the effectiveness of cupping therapy with placebo treatments.

In this new study and for the first time, scientists used functional magnetic resonance imaging (fMRI) combined with a standard clinical trial design to derive an unbiased brain - based neurological marker to predict analgesia associated with placebo treatment in patients with chronic knee osteoarthritis pain.

Study participants (n = 146; 101 males, 45 females) were enrolled in a 16 - week randomized clinical trial comparing naltrexone with placebo treatment.

Not exact matches

In a 564 - person trial, patients whose ovarian cancer recurred (and who had already started treatment with chemotherapy) given Rubraca, part of a new class of cancer drugs called «PARP» inhibitors, lived, on median, for double the amount of time without their disease getting even worse compared with those given a placebo.

In a late - stage study, Aimmune, a biotech immunotherapy allergy treatment taken via pill, found that of the roughly 500 kids with peanut allergies between the ages of 4 - 17 who were part of the trial, 67 % of those who received the treatment were able to tolerate 600 milligrams of peanut protein (about two to four peanuts) after about a year of treatment, while only 4 % of those who got the placebo could tolerate that dose of peanut protein.

Patisiran was being evaluated in a late - stage study against a placebo for the treatment of patients with hereditary ATTR (hATTR) amyloidosis with polyneuropathy.

He contributes to other large - scale clinical trials including SAVE (evaluating whether treatment of obstructive sleep apnoea with continuous positive airways pressure can reduce the incidence of serious CV events in patients with established CVD), and CREDENCE, a randomised, double - blind, placebo - controlled trial assessing whether canagliflozin can slow the progression of diabetic nephropathy in patients with type 2 diabetes.

Of them all, giving your baby a probiotic is perhaps the one treatment that just might help, although a very recent double - blind, placebo - controlled randomized trial in Australia concluded that «L reuteri DSM 17938 did not benefit a community sample of breastfed infants and formula fed infants with colic.»

Long - term treatment with probiotics in primary care patients with irritable bowel syndrome — a randomised, double - blind, placebo controlled trial.

In a second study of 18 children with peanut allergies, the researchers gave the peanut protein treatment to 12 children and placebo powder to the other six.

Treatment with zoledronic acid was associated with an eight percent increase in lumbar spine bone marrow density at 12 weeks relative to the placebo arm, with an 11 percent increase at 24 and 48 weeks.

Treatment with zoledronic acid was associated with a 73 percent and a 65 percent reduction in bone loss relative to placebo at 12 weeks and 24 weeks respectively, an effect that lasted throughout the 48 weeks of the study.

With two additional years of denusomab treatment, their bone mineral density increased further and the wrist fracture rate declined to levels significantly lower than the FREEDOM placebo rate (rate ratio = 0.57, 95 % CI = 0.34 - 0.95; p = 0.03).

Hep C patients being treated for opioid addiction achieved high rates of sustained virologic response after 12 weeks of therapy with elbasvir - grazoprevir compared to those taking placebo for 12 weeks before beginning the drug treatment.

In the four weeks after the first treatments, people had about 15 percent fewer days of headache compared with a placebo or dummy injection.

Researchers here recruited thirty patients with primary insomnia, who underwent neurofeedback treatment and placebo - feedback treatment over several weeks.

Patients with cirrhosis were enrolled in 2 cohorts: HCV treatment - naive or HCV treatment - experienced; patients within each cohort were also stratified according to HCV genotype 1 subtype (1a or 1b) and randomly assigned to receive weight - based ribavirin (1,000 - 1,200 mg / d) or matching placebo.

Alternatively, the Institute investigated the benefit and harm of treatment of ASB detected by screening compared with non-treatment or placebo.

With so much on the line, athletes are willing to try new treatments that may be groundbreaking cures or just elaborate placebos.

«Our results show that the number of responders was three times higher when correct information was given than when patients thought they were treated with an ineffective active placebo, even though the pharmacological treatment was identical,» says author Vanda Faria.

The study was not powered to demonstrate a treatment effect on kidney function, but there was no evidence of a benefit associated with bosutinib compared with placebo over the 2 - year treatment period.

In a related Editor's Note, Deborah Grady, M.D., M.P.H., a deputy editor of JAMA Internal Medicine, writes: «It is possible that treatment beyond one year would result in better outcomes, but these data provide no support for use of higher - dose cholecalciferol replacement therapy or indeed any dose of cholecalciferol compared with placebo.»

TRINOVA - 2 is evaluating pegylated liposomal doxorubicin in combination with either placebo or trebananib in previously treated patients with ovarian cancer while TRINOVA - 3, also known as ENGOT - Ov2 and Gynecologic Oncology Group — 3001, is studying the use of trebananib in front - line treatment adding it to carboplatin / paclitaxel.

The overall risk of nausea and vomiting within 24 hours was about 60 percent lower with gabapentin, compared to inactive placebo (or other treatments).

After nine hours, iron in the blood stream had decreased in the placebo group, whereas this decrease could be prevented by treatment with lexaptepid.

While the treatment did have some favorable effects, in the main measure of outcome — measured with a cognitive test called the Alzheimer's Disease Assessment Scale - cognitive subscale — the researchers did not observe any statistically significant benefit compared with placebo.

The patients were randomized to treatment and control arms at a 2:1 ratio (with 345 treated and 172 receiving placebo).

Furthermore, the report accuses the British Homeopathic Association (BHA), which had submitted evidence to the panel, of cherry - picking, and even, in one case actively misrepresenting, research into the treatment (a famous study that concluded its findings were «compatible with the notion that the clinical effects of homeopathy are placebo effects» was cited by the BHA as evidence of the treatment's efficacy.)

Psoriasis patients were randomly divided into two groups, with 21 patients in the placebo group and 22 patients receiving the treatment.

At the end of treatment, the women who received the drug reported a 21 - point reduction on a standard scale of depression symptoms, compared with about 9 points for the women on a placebo.

For individuals with mild - to - moderate depression, they found that treatment with an antidepressant was almost no different from placebo.

However, if SSRIs had indeed acted merely by means of a placebo effect, these drugs should not outperform actual placebo in clinical trials where patients have been treated with an SSRI or with ineffective placebo pills, and where neither the physician nor the patient knows which treatment the patient has been given until the study is over.

Patients taking part in the study will receive either Genistein Aglycone or placebo (an inactive substance that looks like the treatment) with food, over a period of 12 months.

Six weeks of treatment by the highest dose of dronabinol (10 milligrams) was associated with a lower frequency of apneas or hypopneas (overly shallow breathing) during sleep, decreased subjective sleepiness and greater overall treatment satisfaction compared to the placebo group.

Importantly, compared to placebo, treatment with FCM was also associated with a significant 61 % reduction in the risk of hospitalisation due to worsening heart failure (hazard ratio [HR] 0.39; p = 0.009).

Contrary to the proclamations of many scientists, unreliable medical study results do not disappear with large, randomized controlled trials, in which subjects are randomly assigned to a treatment or placebo group.

Preliminary data show that all executive function domains, except managing affective interference, showed a significant reduction in severity of symptoms during active LDX treatment versus treatment with placebo.

The study of 826 women with previously unexplained recurrent miscarriage showed that those who received progesterone treatment in early pregnancy were no less likely to miscarry than those who received a placebo.

According to the trial's crossover design, patients with refractory chronic cough of at least eight weeks» duration were randomly assigned initially to either AF - 219 or placebo treatment twice daily for two weeks, followed by a washout period, and further followed by crossover to the alternative treatment arm (AF - 219 or placebo) for an additional two weeks.

In a review article published in 2010, physician Max H. Pittler of the German Cochrane Center at the University of Freiburg and physician Edzard Ernst of the Peninsula Medical School in Exeter, England, analyzed 12 well - designed studies comparing kava with a placebo for the treatment of anxiety.

Afferent Pharmaceuticals today announced publication of results from a Phase 2 clinical trial demonstrating that the company's novel drug candidate, AF - 219, reduced daytime cough frequency by 75 % compared to placebo in patients with treatment - refractory chronic cough.

But by 2004, after researchers had completed two major parts of the Women's Health Initiative — which together formed a massive study of 27,347 women that compared treatment with a placebo in a scientifically rigorous way — doctors realized hormone therapy does more harm than good in most women over the long term.

Among cigarette smokers not willing or able to quit smoking in the next month but willing to reduce with the goal of quitting in the next 3 months, use of the nicotine addiction medication varenicline for 24 weeks compared with placebo produced greater reductions in smoking prior to quitting and increased smoking cessation rates at the end of treatment and at 1 year, according to a study in the February 17 issue of JAMA.

«Cold water in the left ear significantly increased patients» insight and awareness of their schizophrenia, which we measured 30 minutes after the test, compared with the sham or placebo treatment using room temperature water,» says Dr. Gerretsen.

Changhai Ding, M.D., Ph.D., of the University of Tasmania, Hobart, Tasmania, Australia, and colleagues randomly assigned 413 patients with symptomatic knee osteoarthritis and low 25 - hydroxyvitamin D to receive monthly treatment with oral vitamin D3 (50,000 IU; n = 209) or an identical placebo (n = 204) for 2 years.

The researchers found that the addition of vitamin D3 to ciclesonide did not significantly reduce the rate of first treatment failure (a composite outcome of decline in lung function and increases in use of beta - agonists, systemic steroids, and health care utilization) compared with placebo; 28 percent and 29 percent of participants in each group, respectively, experienced at least 1 treatment failure during 28 weeks.

«It's difficult for experimental drugs to prove their superiority to placebo treatment and predicting placebo responders may help to deal with this challenge,» says Luana Colloca at the National Institutes of Health in Bethesda, Maryland.

Mario Castro, M.D., M.P.H., of the Washington University School of Medicine, St. Louis, and colleagues randomly assigned adults with asthma and low vitamin D levels to vitamin D3 (100,000 IU once, then 4,000 IU / daily for 28 weeks; n = 201) or placebo (n = 207), which was added to treatment with the inhaled corticosteroid ciclesonide.

What the NINDS study showed, Genentech spokesperson Krysta Pellegrino says, is that «patients were at least 30 percent more likely to have a decrease in stroke - related disability three months after treatment compared with placebo.»

For the «Treatment of Severe Childhood Aggression (TOSCA) Study,» 168 children (ages 6 - 12) who had been diagnosed with ADHD and disruptive behavior disorder (DBD) and displayed severe physical aggression were randomly assigned to two groups: parent training plus stimulant plus placebo (Basic treatment) or parent training plus stimulant plus the antipsychotic drug risperidone (Augmented trTreatment of Severe Childhood Aggression (TOSCA) Study,» 168 children (ages 6 - 12) who had been diagnosed with ADHD and disruptive behavior disorder (DBD) and displayed severe physical aggression were randomly assigned to two groups: parent training plus stimulant plus placebo (Basic treatment) or parent training plus stimulant plus the antipsychotic drug risperidone (Augmented trtreatment) or parent training plus stimulant plus the antipsychotic drug risperidone (Augmented treatmenttreatment).